Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases

Vedolizumab, a monoclonal antibody directed against integrin α4β7, is an effective treatment for inflammatory bowel diseases. However, a significant number of patients do not achieve steroid-free clinical remission in the first year of treatment. An early identification of these patients is one of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Bertani, Lorenzo, Caviglia, Gian Paolo, Antonioli, Luca, Pellicano, Rinaldo, Fagoonee, Sharmila, Astegiano, Marco, Saracco, Giorgio Maria, Bugianesi, Elisabetta, Blandizzi, Corrado, Costa, Francesco, Ribaldone, Davide Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290461/
https://www.ncbi.nlm.nih.gov/pubmed/32370274
http://dx.doi.org/10.3390/jcm9051323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290461/
https://www.ncbi.nlm.nih.gov/pubmed/32370274
http://dx.doi.org/10.3390/jcm9051323

Ejemplares similares